Teva reorganization 'complete', copaxone not ‘elephant’
This article was originally published in Scrip
The Teva Pharmaceutical Industries train "has left the station", according to CEO Jeremy Levin. Speaking at the Goldman Sachs Healthcare Conference on 13 June, he said Teva's new management team was fully in place, all the major steps in reorganizing the company had been completed, and having stabilized the company, "we've started to look very aggressively to the future".
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.